Zymeworks Reports Q3 Revenue of $256.5 Million, Raises 2026 Guidance
Zymeworks reported Q3 2026 revenue of $256.5 million versus analyst expectations of $227.4 million and EPS of $2.28 versus consensus of $2.27. It raised 2026 revenue guidance to $337 million–$351 million and Adjusted EBITDA guidance to $176 million–$190 million.
Zymeworks reported third-quarter 2026 revenue of $256.5 million, exceeding analyst expectations of $227.4 million, and earnings per share of $2.28, compared to the consensus estimate of $2.27. Following these results, the company raised its 2026 total revenue guidance to a range of $337 million to $351 million and its Adjusted EBITDA guidance to $176 million to $190 million. The company also highlighted the completion of its acquisition of Theravance Biopharma on September 23, 2026, which is expected to reduce future operating expenses by $13 million to $15 million annually.
Additionally, Zymeworks noted recent progress with its ZW209 program, which entered an exclusive global collaboration and license agreement with Roche in October 2026.